NURO Key Stats
- NeuroMetrix's CEO Discusses Q12013 Results - Earnings Call Transcript Seeking Alpha Apr 25
- NeuroMetrix Inc. Earnings Call scheduled for 8:00 am ET today Apr 25
- Q1 2013 NeuroMetrix Inc. Earnings Release - Before Market Open Apr 25
- NeuroMetrix Reports Q1 2013 Results Business Wire Apr 25
- NeuroMetrix to Partner with Omron Healthcare for Distribution of NC-stat DPNChec... Apr 24
- NeuroMetrix, Inc. Announces Date for 2013 First Quarter Financial Results Confer... Apr 17
- Wall Street Transcript Interview with Shai N. Gozani, President, CEO and Directo... Mar 15
- NeuroMetrix Enters Exclusive Distribution Agreement with Handok Pharmaceuticals ... Mar 12
- NeuroMetrix Partners with Handok Pharmaceuticals for NC-stat DPNCheck Distributi... Mar 12
- NEUROMetrix (NURO) Files $20M Mixed Shelf Street Insider Feb 25
NURO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NeuroMetrix is down 51.02% over the last year vs S&P 500 Total Return up 27.96%, Medtronic up 43.00%, and C.R. Bard up 6.91%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for NURO
Pro Report PDF for NURO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NURO Pro Report PDF
Pro Strategies Featuring NURO
Did NeuroMetrix make it into our Pro Portfolio Strategies?